An ISO9001 Certified Supplier of Pharmaceutical Ingredients and Specialty Chemicals

ENSACOVE®

Drug Information Related Patent
Hold Company
XCOVERY
Learn More
Dosage and Administration
CAPSULE;ORAL
Specification
EQ 25MG BASE; EQ 100MG BASE
Indication
Ensacove® is indicated for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive locally advanced or metastatic non-small cell lung cancer (NSCLC) who have not previously received an ALK-inhibitor.
Use
Instructions for Use
API
ENSARTINIB HYDROCHLORIDE
API Structure
We Supply
ENSARTINIB
Drug Patent
Patent NoExpiration Date
108997442037/6/1
85519952029/2/9
91269472031/11/29
92967242029/6/18
API Patent
Patent NoExpiration Date
85519952029/2/9
91269472031/11/29
92967242029/6/18

Note: The patent information provided herein is derived solely from publicly available data in the FDA Orange Book (or other cited sources) and is presented for general informational purposes only. Actual patent status may vary based on jurisdictional rulings, regulatory extensions or other factors.

HOURS

Daily: 9.30 AM–6.00 PM
Sunday : 9.30 AM–1.00 PM
Holidays: Closed

INFORMATION
CONTACT US
  • Tel:
  • E-mail:
  • Address:
  • WhatsAPP
    WhatsAPP
Privacy Policy | Cookie Policy
Copyright © Protheragen. All Rights Reserved.
Member of
dcat
CERTIFICATION
dcat
dcat dcat dcat dcat
Top